<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02738658</url>
  </required_header>
  <id_info>
    <org_study_id>20151810</org_study_id>
    <nct_id>NCT02738658</nct_id>
  </id_info>
  <brief_title>Comparison of the Vasomotor Function and Myocardial Flow in Patients Treated With Bioresorbable and Metallic Stents at 1 Year</brief_title>
  <acronym>BVS-Flow</acronym>
  <official_title>Comparison of the Vasomotor Function and Myocardial Flow in Patients Treated</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundació La Marató de TV3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigació Biomèdica de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: A total of 25-50% of patients with stable coronary atherosclerosis treated with
      metallic stent implantation remain with effort angina despite optimal medical treatment and
      absence of stent restenosis at 1 year. The most plausible cause of persistent effort angina
      after stent implantation is microcirculatory dysfunction. Coronary circulation matches the
      myocardial blood supply and oxygen consumption. Metallic stent implantation has been related
      with endothelial dysfunction and impaired coronary blood flow reserve (relation between
      coronary blood flow at rest and maximal hyperemia) of the treated vessel at 1 year.

      Bioresorbable Vascular Scaffold (BVS) has been shown to improve the endothelial function and
      to improve the angina symptoms at 1 year. However, the coronary blood flow of BVS has never
      been tested.

      Main objective: To determine differences in the blood average peak velocity at maximal
      hyperemia with adenosine infusion between patients treated with bioresorbable and metallic
      coronary stents at 1 year after stent implantation.

      Methodology: A total of 70 patients are 1:1 randomized to everolimus-eluting metallic stent
      (EES) versus everolimus-eluting BVS implantation in patients with stable coronary disease. At
      1 year, patients undergo to invasive coronary angiography prior cessation of vasomotor drugs.
      A pressure/Doppler wire is advanced distally to the &quot;treated segment&quot; and the endothelial
      (acetylcholine) and non-endothelial (adenosine and nitroglycerine) vasomotor function is
      assessed with quantitative coronary angiography and pressure and Doppler measurements. Angina
      test questionnaires are obtained at different time-points of the study.

      Expected results: A difference between patients treated with BVS and EES of 12.0 cm/sc in the
      maximal average peak velocity (APV) under maximal hyperemia (with adenosine administration)
      is expected, as assessed by Doppler measurements, at 1 year after stent implantation. The
      study is powered to assess superiority in terms of maximal APV favoring patients treated with
      BVS.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the average peak velocity at maximal hyperemia between bioresorbable vascular scaffolds and everolimus-eluting stents as assessed by doppler wire measurement.</measure>
    <time_frame>1-year after stent implantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in endothelial dysfunction with acetyl-choline infusion between bioresorbable vascular scaffolds and everolimus-eluting stents as assessed by quantitative coronary angiography (4% of lumen reduction)</measure>
    <time_frame>1-year after stent implantation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Difference in fractional flow reserve at maximal hyperemia between the two treatment groups as assessed by pressure-wire measurement</measure>
    <time_frame>1-year after stent implantation</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Stable Angina</condition>
  <arm_group>
    <arm_group_label>Bioresorbable vascular scaffold (BVS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with stable coronary angina with coronary artery disease suitable to be treated with a bioresorbable vascular scaffold.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus-eluting stent (EES)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with stable coronary angina with coronary artery disease suitable to be treated with a Everolimus-eluting stent .</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioresorbable vascular scaffold</intervention_name>
    <arm_group_label>Bioresorbable vascular scaffold (BVS)</arm_group_label>
    <other_name>Bioresorbable stents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent</intervention_name>
    <arm_group_label>Everolimus-eluting stent (EES)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with stable angina or silent angina with myocardial ischemia detected by
             non-invasive tests or patients with acute coronary syndromes with no increase of &gt; 5
             times the upper value of normality of cardiac biomarkers (troponin).

          -  Patients with coronary artery disease with angiographic stenosis &gt;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L´Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08173</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigació Biomèdica de Bellvitge</investigator_affiliation>
    <investigator_full_name>Josep Gomez Lara</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Coronary microcirculatory dysfunction</keyword>
  <keyword>Coronary endothelium dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

